脂蛋白(a)水平与二十碳五烯酸乙酯降低心血管风险的关系
REDUCE-IT事后分析纳入7,026例接受他汀治疗、甘油三酯1.69-5.63 mmol/L且LDL-C 1.06-2.59 mmol/L的高危患者,评估基线Lp(a)与MACE风险及IPE疗效的关系。结果显示Lp(a)与首次和总MACE显著相关(P<0.0001),而IPE在不同Lp(a)水平(≥50或<50 mg/dL)均显著减少首次MACE,交互作用P>0.10。
要点
- 基线Lp(a)水平与首次及总MACE风险显著相关(P<0.0001)。
- IPE降低MACE的效应在不同Lp(a)范围内一致(交互P>0.10)。
- Lp(a)≥50 mg/dL亚组中IPE仍显著减少首次MACE。
核心结论
- 在接受他汀治疗且甘油三酯升高的高危患者中,基线Lp(a)浓度对MACE具有预后价值。
- IPE在不同Lp(a)水平(包括临床相关升高)均一致降低MACE风险。
研究设计与样本
- REDUCE-IT试验的事后分析,共纳入8,179例接受他汀治疗、确诊心血管疾病或年龄≥50岁伴糖尿病且≥1项额外危险因素、空腹甘油三酯1.69-5.63 mmol/L、LDL-C 1.06-2.59 mmol/L的参与者。
- 参与者随机接受IPE 2 g每日两次或匹配安慰剂。
- 其中7,026例(占随机人群86%)有基线Lp(a)评估数据,中位浓度11.6 mg/dL(Q1-Q3:5.0-37.4 mg/dL)。
主要发现
- 基线Lp(a)与首次MACE及总MACE均存在显著关系(P<0.0001)。
- IPE对事件的降低效应在不同Lp(a)范围内无显著差异(交互作用P>0.10)。
- 在Lp(a)≥50 mg/dL和<50 mg/dL亚组中,IPE均显著减少首次MACE。
临床怎么用
- 对于接受他汀治疗且甘油三酯升高的高危患者,基线Lp(a)可用于MACE风险分层。
- 无论Lp(a)水平高低(包括≥50 mg/dL),IPE均可考虑用于降低MACE风险。
局限性
- 为REDUCE-IT的事后分析,结果需前瞻性验证。
- 仅7,026例(86%)有基线Lp(a)数据,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elevated lipoprotein(a) (Lp[a]) concentrations are associated with increased cardiovascular event risk even in the presence of well-controlled low-density lipoprotein cholesterol levels, but few treatments are documented to reduce this residual risk. OBJECTIVES: The aim of this post hoc analysis of REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial) was to explore the cardiovascular benefit of icosapent ethyl (IPE) across a range of Lp(a) levels. METHODS: A total of 8,179 participants receiving statin therapy with established cardiovascular disease or age ≥50 years with diabetes and ≥1 additional risk factor, fasting triglyceride 1.69 to 5.63 mmol/L, and low-density lipoprotein cholesterol 1.06 to 2.59 mmol/L were randomized to receive 2 g twice daily of IPE or matching placebo. Relationships between continuous baseline Lp(a) mass concentration and risk for first and total (first and subsequent) major adverse cardiovascular events (MACE) were analyzed, along with the effects of IPE on first MACE among those with Lp(a) concentrations ≥50 or <50 mg/dL. RESULTS: Among 7,026 participants (86% of those randomized) with baseline Lp(a) assessments, the median concentration was 11.6 mg/dL (Q1-Q3: 5.0-37.4 mg/dL). Lp(a) had significant relationships with first and total MACE (P < 0.0001), while event reductions with IPE did not vary across the range of Lp(a) (interaction P > 0.10). IPE significantly reduced first MACE in subgroups with concentrations ≥50 and <50 mg/dL. CONCLUSIONS: Baseline Lp(a) concentration was prognostic for MACE among participants with elevated triglyceride levels receiving statin therapy. Importantly, IPE consistently reduced MACE across a range of Lp(a) levels, including among those with clinically relevant elevations.
引用
- Szarek M, Bhatt DL, Miller M, et al. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. J Am Coll Cardiol. 2024. PMID: 38530686. doi:10.1016/j.jacc.2024.02.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。